Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
1. Eli Lilly to commence late-stage trials for eloralintide next month. 2. High-dose eloralintide showed 20.1% weight loss at 48 weeks. 3. Market competition intensifies with Novo Nordisk and Pfizer's rival drugs. 4. Amylin analogs may lead to next-gen obesity treatment alternatives. 5. Eli Lilly's safety data on side effects is still pending.